Adial Pharmaceuticals Valuation
| ADIL Stock | USD 2.85 0.18 5.94% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. Adial Pharmaceuticals shows a prevailing Real Value of $13.19 per share. The current price of the firm is $2.85. Our model approximates the value of Adial Pharmaceuticals from analyzing the firm fundamentals such as Current Valuation of (1.44 M), shares owned by insiders of 2.08 %, and Return On Equity of -1.55 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Adial Pharmaceuticals' valuation include:
Undervalued
Today
Please note that Adial Pharmaceuticals' price fluctuation is somewhat reliable at this time. Calculation of the real value of Adial Pharmaceuticals is based on 3 months time horizon. Increasing Adial Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Adial stock is determined by what a typical buyer is willing to pay for full or partial control of Adial Pharmaceuticals. Since Adial Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Adial Stock. However, Adial Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.85 | Real 13.19 | Target 44.33 | Hype 2.46 |
The intrinsic value of Adial Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Adial Pharmaceuticals' stock price.
Estimating the potential upside or downside of Adial Pharmaceuticals helps investors to forecast how Adial stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Adial Pharmaceuticals more accurately as focusing exclusively on Adial Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Adial Pharmaceuticals' intrinsic value based on its ongoing forecasts of Adial Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Adial Pharmaceuticals' closest peers.
Adial Pharmaceuticals Cash |
|
Adial Pharmaceuticals Total Value Analysis
Adial Pharmaceuticals is presently forecasted to have valuation of (1.44 M) with market capitalization of 3.17 M, debt of 975.86 K, and cash on hands of 9.16 M. The negative valuation of Adial Pharmaceuticals may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Adial Pharmaceuticals fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(1.44 M) | 3.17 M | 975.86 K | 9.16 M |
Adial Pharmaceuticals Asset Utilization
One of the ways to look at asset utilization of Adial is to check how much profit was generated for every dollar of assets it reports. Adial Pharmaceuticals shows a negative utilization of assets of -0.79 percent, losing $0.007936 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Adial Pharmaceuticals shows how discouraging it operates for each dollar spent on its assets.Adial Pharmaceuticals Profitability Analysis
Based on Adial Pharmaceuticals' profitability indicators, Adial Pharmaceuticals may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in March. Profitability indicators assess Adial Pharmaceuticals' ability to earn profits and add value for shareholders.Net Loss | First Reported 2015-12-31 | Previous Quarter -2 M | Current Value -1.8 M | Quarterly Volatility 1.9 M |
For Adial Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Adial Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Adial Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Adial Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Adial Pharmaceuticals over time as well as its relative position and ranking within its peers.
Adial Pharmaceuticals Earnings per Share Projection vs Actual
The next projected EPS of Adial Pharmaceuticals is estimated to be -3.116675 with future projections ranging from a low of -3.225 to a high of -3.0. Adial Pharmaceuticals' most recent 12-month trailing earnings per share (EPS TTM) is at -15.0. Please be aware that the consensus of earnings estimates for Adial Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Adial Pharmaceuticals Earnings Estimation Breakdown
The calculation of Adial Pharmaceuticals' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Adial Pharmaceuticals is estimated to be -3.116675 with the future projection ranging from a low of -3.225 to a high of -3.0. Please be aware that this consensus of annual earnings estimates for Adial Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-3.23 Lowest | Expected EPS | -3 Highest |
Adial Pharmaceuticals Earnings Projection Consensus
Suppose the current estimates of Adial Pharmaceuticals' value are higher than the current market price of the Adial Pharmaceuticals stock. In this case, investors may conclude that Adial Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Adial Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 3 | 42.14% | -0.08 | -3.116675 | -15.0 |
Adial Pharmaceuticals Ownership Allocation
Almost 94.59 percent of Adial Pharmaceuticals outstanding shares are held by general public with 2.08 (percent) owned by insiders and only 3.33 % by other corporate entities.Adial Pharmaceuticals Profitability Analysis
Net Loss for the year was (13.2 M) with profit before overhead, payroll, taxes, and interest of 0.About Adial Pharmaceuticals Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Adial Pharmaceuticals. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Adial Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing Adial Pharmaceuticals's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Adial Pharmaceuticals's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Adial Pharmaceuticals. We calculate exposure to Adial Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Adial Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | (508.50) | (533.93) |
Adial Pharmaceuticals Current Valuation Indicators
Adial Pharmaceuticals' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Adial Pharmaceuticals' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Adial Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Adial Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Adial Pharmaceuticals' worth.When determining whether Adial Pharmaceuticals is a strong investment it is important to analyze Adial Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Adial Pharmaceuticals' future performance. For an informed investment choice regarding Adial Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adial Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adial Pharmaceuticals. If investors know Adial will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Adial Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Adial Pharmaceuticals's market price often diverges from its book value, the accounting figure shown on Adial's balance sheet. Smart investors calculate Adial Pharmaceuticals' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Adial Pharmaceuticals' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that Adial Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Adial Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Adial Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.